The Europe Anticoagulant Reversal Drugs Market would witness market growth of 12.9% CAGR during the forecast period (2021-2027). Anticoagulant drugs are widely used for treatment and ¬prevention of thromboembolic problems. So, these patients do require anticoagulant reversal drugs for management of bleeding. While taking anticoagulation reversal, it is must to consider aspects such as the anticoagulant type, dose, and the timings of the last dose.
Undesirable bleeding is one of the major concerns and complications of anticoagulant therapy. The possibility of bleeding differs from person to person as well as with the type of anticoagulant agent being taken. The anticoagulant reversal drugs market has been flourished in recent years due to the aspects such as the launch and approval of novel therapies and the increasing occurrence of bleeding disorders. The incidence of indications for anticoagulant therapy is also increasing which is contributing to the demand for the anticoagulant reversal drugs.
According to the British Heart Foundation Centre, 2018 report, it was estimated that there were around 7.4 million people suffering from heart and circulatory diseases in the United Kingdom. Also, 43,000 people below the age of 75 died of heart and circulatory diseases in the United Kingdom each year. The Human medicines committee of European Medical Association has approved the conditional marketing authorization of Ondexxya (andexanet alfa) in the European Union. This medicine used as an antidote for adult patients who need to have a reversal of anticoagulant (clot-preventing) in the emergency situation of life-threatening or uncontrolled bleeding. The increasing prevalence of atrial fibrillation (AFiB) and rising risk of stroke in the UK are the major driving factors for the anticoagulant reversal drug market in Europe. Though, the market is likely to experience slow growth in coming years due to the high cost of anticoagulant reversal drugs.
The Germany market dominated the Europe Prothrombin Complex Concentrates Market by Country in 2020, thereby, achieving a market value of $16.3 million by 2027. The UK market is showcasing a CAGR of 12.5% during (2021-2027). Additionally, The France market is anticipated to witness a CAGR of 14.9% during (2021-2027).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product Type, the market is segmented into Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Anticoagulant Reversal Drugs Market Size will Hit $1.6 Billion by 2027, at a CAGR of 13.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, CSL Limited, Bausch Health Companies, Inc., Octapharma AG, Pfizer, Inc., Fresenius SE & Co. KGaA, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), Dr. Reddy’s Laboratories Ltd., AMAG Pharmaceuticals, Inc. (Covis Pharma), and Alps Pharmaceutical Ind. Co., Ltd.
By Distribution Channel
By Product Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
